MENLO PARK, Calif.--(BUSINESS WIRE)--OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for severe metabolic disorders, today announced preliminary safety and ...
PALO ALTO, Calif.--(BUSINESS WIRE)--OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for severe metabolic disorders, today announced completion of the second cohort of ...
TLC-6740 is a novel, oral, liver-targeted mitochondrial protonophore in development for obesity and related metabolic diseases, including diabetes and MASH. By increasing energy expenditure through ...
TLC-6740 is a novel, oral, liver-targeted mitochondrial protonophore in development for obesity and related metabolic diseases, including diabetes and MASH. By increasing energy expenditure through ...
Novel preclinical findings for TLC-1180 demonstrate exercise-mimetic, insulin-sensitizing, and cognition-preserving effects OrsoBio, Inc. (“OrsoBio” or “the Company”), a clinical-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results